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Technologies for profiling samples using different omics platforms have been at the forefront
since the human genome project. Large-scale multi-omics data hold the promise of
deciphering different regulatory layers. Yet, while there is a myriad of bioinformatics tools,
each multi-omics analysis appears to start from scratch with an arbitrary decision over
which tools to use and how to combine them. Therefore, it is an unmet need to
conceptualize how to integrate such data and implement and validate pipelines in different
cases. We have designed a conceptual framework (STATegra), aiming it to be as generic
as possible for multi-omics analysis, combining available multi-omic anlaysis tools (machine
learning component analysis, non-parametric data combination, and a multi-omics
exploratory analysis) in a step-wise manner. While in several studies, we have previously
combined those integrative tools, here, we provide a systematic description of the
STATegra framework and its validation using two The Cancer Genome Atlas (TCGA) case
studies. For both, the Glioblastoma and the Skin Cutaneous Melanoma (SKCM) cases,
we demonstrate an enhanced capacity of the framework (and beyond the individual tools)
to identify features and pathways compared to single-omics analysis. Such an integrative
multi-omics analysis framework for identifying features and components facilitates the
discovery of new biology. Finally, we provide several options for applying the STATegra
1

March 2021 | Volume 12 | Article 620453

Planell et al.

STATegra: Multi-Omics Data Integration Framework

framework when parametric assumptions are fulfilled and for the case when not all the
samples are profiled for all omics. The STATegra framework is built using several tools,
which are being integrated step-by-step as OpenSource in the STATegRa Bioconductor
package.1
Keywords: multi-omic analyses, data-integration,
non-parametric combination, GeneSetCluster

next-generation

sequencing,

component

analysis,

https://bioconductor.org/packages/release/bioc/html/STATegra.html
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INTRODUCTION

and developed. Furthermore, as described in the framework,
additional tools are planned to be incorporated into the
Bioconductor package, e.g., the pESCA (Song et al., 2020) for
multi-omics CA and the GeneSetCluster (Ewing et al., 2020)
for multi-omics exploratory analysis.
To demonstrate the added value of the STATegra framework
as a whole, we applied it to two data-sets from The Cancer
Genome Atlas (TCGA): the glioblastoma data-set (Turcan et al.,
2012) and the melanoma data-set (Akbani et al., 2015). We also
explored (i) the use of samples for which only a subset of
omics profiles is available and (ii) the use of parametric vs.
non-parametric analysis.

Computational and experimental developments have enabled
the profiling of multiple layers of cell regulation: genome,
transcriptome, epigenome, chromatin conformation or
metabolome, among many globally known “omics” (Ramos
et al., 2017; Gomez-Cabrero et al., 2019). The development
of such technologies was driven by the understanding that a
single-omic does not provide enough information to allow
dissecting biological mechanisms (Joyce and Palsson, 2006;
Gomez-Cabrero et al., 2014). For instance, while specific DNA
variations have been linked with multiple diseases, the associated
mechanisms are not fully understood (Gilad et al., 2008; James
et al., 2018). As a result, multi-omics data-sets are increasingly
applied across biological domains such as cancer biology
(Gerstung et al., 2015; Tomczak et al., 2015; Iorio et al., 2016;
Mertins et al., 2016; de Anda-Jáuregui and Hernández-Lemus,
2020). Furthermore, single-cell multi-omics analysis (Macaulay
et al., 2017; Colomé-Tatché and Theis, 2018; Chen et al., 2019;
Welch et al., 2019) has just become a reality.
However, from the necessity of multi-omics profiling came
the need for multi-omics analysis tools. Thus, integrative approaches
are expected to generate significantly more comprehensive insights
into the biological systems under study (SuS). A myriad of such
tools in the literature may be categorized and classified differently
(possibly in complex ways; Gomez-Cabrero et al., 2014; HofmannApitius et al., 2015; Kannan et al., 2016; Meng et al., 2016;
Rohart et al., 2017; Argelaguet et al., 2018; Stein-O’Brien et al.,
2018). While each of the tools is a valuable resource for any
multi-omics research, combining them into a conceptually unified
framework is key. Equally important is the fact that each framework
must be as generic as possible. Thus, we introduce the STATegra
framework, in which we integrate three multi-omics based
approaches into a single pipeline: (a) Component Analysis (CA)
to understand the coordination among omics data-types (Måge
et al., 2019); (b) Non-Parametric Combination (NPC) analysis
to leverage on paired designs to increase statistical power
(Karathanasis et al., 2016); and (c) an integrative exploratory
analysis (Ewing et al., 2020). Furthermore, this framework may
be extended by including additional tools such as network analysis
(Barabási et al., 2011; Yugi et al., 2016). We incorporated most
of these tools into the STATegRa Bioconductor package to
facilitate their use.2 The package is continuously being updated

MATERIALS AND METHODS
Additional information is included in Supplementary
Material, and an html-R Markdown document is provided
for each data-set in Supplementary Material; each document
provides a comprehensive overview of the code used to enhance
their reproducibility.

Downloading and Preprocessing Data

We selected the Glioblastoma Multiforme (GBM) and the SKCM
data-sets from TCGA. The level 3 publicly available data for
gene expression (gene expression calls), miRNA (miRNA
expression calls), and DNA methylation (beta values per CpG,
DNAm) were obtained per sample through the NCI’s Genomic
Data Commons (GDC) portal (Tomczak et al., 2015). The
associated metadata for each project was also obtained.
Additionally, for the SKCM data-set, curated metadata generated
in a previous TCGA study was also used (Akbani et al., 2015).
Glioblastoma multiforme: three data types were downloaded:
array-based expression (mRNA) – Affymetrix Human Genome
HT U133A, array-based expression (miRNA) – Agilent
Microarray, and array-based DNA Methylation (DNAm) –
Illumina Human Methylation 450 K. The number of available
samples differed depending on the omic: mRNA, miRNA, and
DNAm profiles are available for 523, 518, and 95 samples,
respectively (Supplementary Table 1; Supplementary Figure 2A).
Skin Cutaneous Melanoma: three data types were downloaded:
RNA-seq-based expression (mRNA) – Illumina HiSeq 2000,
miRNA-Seq-based expression (miRNA) – Illumina HiSeq 2000,
and array-based DNA Methylation (DNAm) – Illumina Human
Methylation 450 K. The data from these three omics are available
for all the individuals (n = 425); however, divergences between

https://bioconductor.org/packages/release/bioc/html/STATegra.html
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Non-Parametric Combination for Two
Data-Types (omicsNPC)

the initial date of diagnosis (driving the metadata information)
and
the
TCGA
specimen
date
were
identified
(Supplementary Figure 1). Consequently, we decided to include
only those cases for which specimens were obtained within a
1-year window from diagnosis (n = 104).
Supplementary Table 1 describes the characteristics of the
two data-sets and the pre-processing steps applied before starting
the integrative workflow of multi-omics data. We conducted
an exhaustive exploration for each data type assessing the need
for data normalization and/or filtering (Supplementary Material).
Metadata is available for GBM and SKCM (summarized in
Supplementary Table 2 and described in Supplementary
Tables 3, 4 for a detailed description of the variables). In
general, the data provided by TCGA contains information on
demographic features (age, gender, race, and ethnicity), tumor
characteristics (age at diagnosis, the primary site of the disease,
stage of the neoplasm, prior glioma, ulceration in melanoma,
Karnofsky score for GBM, and Breslow thickness for SKCM),
survival outcome (vital status, days to death, days to the last
follow-up), and technical processes (batch number, tissue source
site – TSS, i.e., centers which collect samples and
clinical metadata).
At the end of the preprocessing, numerous matrices, i.e.,
one matrix per every omics data-type (mRNA, miRNA, and
DNAm), plus one additional matrix containing the metadata
of the samples, compose each data-set (GBM, SKCM). Omics
data-type matrices are arranged placing measurements (a.k.a.
features) on rows and samples in columns, while metadata
matrices include samples as rows and metadata information
(e.g., age, gender, etc.) in columns.

Non-Parametric Combination techniques allow combining
statistical evidence (p-values) across data-types to obtain a
more precise characterization of the changes associated with
the outcome of interest (Karathanasis et al., 2016).
The above-described approach allows to integrating data
matrices defined on overlapping sets of samples. Taking
advantages of this possibility, we explored the NPC following
two strategies: analyzing only common samples or analyzing
all available samples (including non-overlapping ones,
when applicable).
Importantly, NPC methods require linking the features
across data-types. To that end, the relation between mRNA
and miRNA and mRNA and methylation were obtained using
the SpidermiR R package (Cava et al., 2017) and RGmatch
(Furió-Tarí et al., 2016), respectively.
In the case of mRNA and miRNA mapping, different versions
of annotation were found; we combined the following two:
the miRNAmeConverter (Haunsberger et al., 2017) and anamiR
(Wang et al., 2019) R packages.
Finally, the NPC may be run using the omicsNPC function
from the STATegRa package using the two data-types, the
mapping file (i.e., mRNA – miRNA), and the variables to
include in the model (see R-code below) as inputs.
In our analyses, the outcomes of interest were survival for
the GBM data-set and the primary site of tumor for the SKCM
data-set. Additionally, age was included as a co-variable in all
the models. Depending on the nature of the outcome of interest
the analysis performed during NPC differs. In the case of
GBM, the association between each molecular quantity and
the time-to-event was assessed through a Cox Regression model
(Cox, 1972). Since age is by itself a relevant factor (Supplementary
Figure 5), it was treated as a time-varying factor by specifying
a time-transform function (Therneau et al., 2020). In SKCM
associations between each molecular quantity and the primary
site of the tumor were assessed through a differential expression
analysis using Limma (Robinson, 2009; highlighted lines from
the R-code).
-------CODE------# Detailed version of the code is provided as Supplementary
Material (RMarkDown)
#NPC input
mRNA_data #mRNA expression data matrix
miRNA_data #miRNA expression data matrix
mapping_gene #mapping of mRNA to genes
mapping_mirna #mapping of miRNA to genes

Component Analysis for Two Data-Types
(omicsPCA)

To perform joint exploration of data, the two data-types must
fulfill the following criteria: (i) each feature must be scaled
and (ii) only samples that are common to the two data types
can be analyzed. Each feature was mean-centered and then
normalized to the unit sum of squares (Frobenius normalization).
Due to sample availability, component analysis for two datatype matrices was restricted for each analysis for common
samples (Supplementary Figure 2A).
Once input data were ready, the two main omicsPCA steps
were applied: model selection and subspace recovery. For model
selection, we aimed to identify the correct model, which means
the exact number of common (shared) components and the
number of distinctive components per data-type. We investigated
the following methodologies: JIVE (Lock et al., 2013; the jive
R package), PCA-GCA (Gu and Van Deun, 2019; RegularizedSCA
R package), and pESCA (Song et al., 2020; RpESCA and
Rspectra R packages; Supplementary Table 5 and Supplementary
html-R Markdown document).
Finally, the association between metadata and the shared/
individual components obtained was assessed using the KruskalWallis test, Spearman’s correlation, or the Cox regression model,
depending if the variable of interest was categorical, numerical
or time-to-event, respectively.
All analyses were conducted in R (R Core Team, 2017).
Frontiers in Genetics | www.frontiersin.org

#1 – Generate the mapping between mRNA and miRNA; a
data frame describing how to map measurements across data-sets
dataMappingExprMirna <- combiningMappings
(mappings = list(expr = mapping_gene, mirna
= mapping_mirna), retainAll= TRUE, reference
= ‘Gene’)
#2 – Specify data type.
# The type of analysis to be performed is defined here.
3
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# For GBM, as the output of interest is the survival outcome,
we must define a coxph function that considers the age as a
co-variable. This defined function is called “ttCoxphContinuous”
dataTypesExprMirna <- list(ttCoxphContinuous
,ttCoxphContinuous)

content using the relative risk (RR) of each e-set appearing
with each other. Only significant gene-sets (values of p < 0.05)
with a minimum of three genes were selected for functional
exploration. RR scores were clustered into groups using k-means
with the optimal number of genes determined using gap statistics.

#For SKCM, as our output of interest is the differential expression
between primary site of tumor, it is only necessary to define
that our data-types are continuous.
dataTypesExprMirna <- c(expr = ‘continuous’,
mirna = ‘continuous’).

RESULTS
We designed the STATegra framework as a four-step analysis
(Figure 1). In the first step, each data-type was analyzed
separately using state-of-the-art tools for each omic. Next, in
a second step, we explored the shared variability between the
different data-types using unsupervised techniques such as Joint
and Individual Variation Explained (JIVE; Lock et al., 2013),
implemented in OmicsPCA. This analysis provided qualitative
and quantitative insights into how much the different datatypes (e.g., different omics) and their features were “coordinated.”
Moreover, the analysis provided useful information for targeting
specific omics combinations (Gomez-Cabrero et al., 2019). In
the third step, for those combinations of omics characterized
as coordinated, NPC analysis allowed increasing the statistical
power to identify significant features as we have recently
demonstrated (Ewing et al., 2019; Fernandes et al., 2019). For
that purpose, we used the NPC within the omicsNPC function
(Karathanasis et al., 2016). In the final step, clustering tools
(e.g., OmicsClustering) and gene-set enrichment analysis
summarizing tools (such as GeneSetCluster, Ewing et al., 2020)
allowed an integrated approach.

#3 - Preparing the data-sets as an ExpressionSet object (outcome
variable refers to our variable of interest, in that case, “survival”
for GBM data-set and “primary site of tumor” for SKCM
data-set).
mRNA <- createOmicsExpressionSet(Data = mRNA_
data, pData = metadata[,c(“age”,“outcome”)]0029
miRNA <- createOmicsExpressionSet(Data = miRNA_
data, pData = metadata[,c(“age”“outcome”)])
dataInputExprMirna <- list(expr = mRNA, mirna
= miRNA)
#4 - Setting methods to combine p-values
combMethods <- c(“Fisher”,“Liptak”,“Tippett”)
# Setting number of permutations
numPerms <- 1000
# Setting number of cores
numCores <- 4

Selected Case Studies

We selected two case studies: GBM and SKCM. GBM is the
first cancer studied by TCGA (McLendon et al., 2008; Brennan
et al., 2013). The TCGA GBM data-set consists of primary
tumor samples from roughly 600 cases. The data-set contains
gene expression, miRNA, and DNA methylation microarrays.
Several findings have been reported on these data, including
a molecular classification of glioblastoma based on gene
expression profiles (classical, proneural, neural, and mesenchymal;
Verhaak et al., 2010). The TCGA Consortium published the
landscape of SKCM in 2015 (Akbani et al., 2015). The TCGA
SKCM data-set consists of melanoma samples from patients
diagnosed with either primary or metastatic cutaneous melanoma
or metastatic melanoma of unknown primary from ~400 cases.
The data-set contains genotype information, gene expression,
and methylation microarrays. Based on these data, several
findings have been reported, including the genomic identification
of four mutant subtypes (BRAF hotspot, NF1 mutant, RAS
hotspot, and triple wild-type) and a molecular classification
based on gene expression profiles (immune, keratin, and
MITF-low related profiles) associated with survival time. In
general, patients from both studies were Caucasian with a
median age of 58–59 years and a higher proportion of males
(~60%). The mortality rate in GBM was high (78%) with a
median life expectancy of around 1 year. For SKCM, 42% of
patients died during follow-up and median life expectancy
was of 1 year and 3 months (Supplementary Tables 1, 2).

# Setting omicsNPC to print out the steps that it performs.
verbose <- TRUE
#Run the omicsNPC
omicsNPC_output <- omicsNPC(dataInput
dataInputExprMirna,
dataMapping = dataMappingExprMirna,
dataTypes = dataTypesExprMirna,
combMethods = combMethods,
numPerms = numPerms,
numCores = numCores,
verbose = verbose)
-------------------------

=

GeneSetClustering

Significant genes from omicsNPC in the different approaches
(Adj.value of p < 0.05 or Fisher p-value <0.05 in NPC) were
uploaded to the Ingenuity Pathway Analysis (IPA; Krämer
et al., 2014) database (Qiagen), and core expression analysis
was performed to identify affected canonical pathways and
functional annotations. Right-tailed Fisher’s exact test was used
to calculate a p-value. Canonical pathways/functional annotations
were clustered together using GeneSetCluster (Ewing et al.,
2020). Briefly, the gene-sets were grouped into clusters by
calculating the similarity of pathways/annotations of the gene
Frontiers in Genetics | www.frontiersin.org
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FIGURE 1 | Workflow diagram of the multi-omics analysis framework.

Step 1: Independent Data-Type Exploration
and Characterization

one of the first three main components of omics data (refer to
Supplementary Material; Bonferroni adjusted value of p < 0.05):
survival outcome (mRNA, miRNA, DNAm) and TSS (mRNA).
In the case of the SKCM data-set, the two first PCA
components showed a limited amount of variability explained
for all omics (Supplementary Figure 3A). We identified several
clinical variables associated with at least one of the first three
main components of omics data (refer to Supplementary
Material; Bonferroni adjusted value of p < 0.05): primary site
of disease (mRNA, miRNA), neoplasm (mRNA), and pathological
stage of the disease (mRNA, miRNA).
It is worth noting that some of the clinical variables were
associated with at least one of the first three components in the
individual data-type exploration for more than one omics data
type. Such results apply to both GBM and SKCM data-sets.
Consequently, we hypothesize that several omics are coordinated
and their analytical integration would bring more statistical power
and synergistic insights. In Step 2, we investigated such assumptions.

Once the data is pre-processed, we recommend conducting
quality controls for each individual data-type as the first step
in the STATegra framework. In our example we made use of
principal component analysis (PCA) as an unsupervised exploratory
analysis. However, other matrix-factorization techniques may
be used, e.g., Independent Component Analysis (ICA; Lee and
Batzoglou, 2003) or Non-negative Matrix Factorization (NMF;
Lee and Seung, 1999). It is important to emphasize the relevance
of setting up a proper study design to avoid possible batcheffects not to be confounded with the biological effects under
study: a component analysis will not overcome a wrong design.
In the GBM data-set case, the two first PCA components
showed a limited amount of variability explained for all omics
(Supplementary Figure 2B), suggesting a large per sample
variability. As expected from the original TCGA publication
(Verhaak et al., 2010), we found a significant association between
the previously defined “gene expression subtypes” (Verhaak et al.,
2010) and the first PCs of mRNA (Bonferroni adjusted value
of p < 0.001; refer to Supplementary Material). Interestingly,
such association was also found for miRNA and DNAm
(Supplementary Figure 2C; adjusted value of p < 0.005). Moreover,
we identified several clinical variables associated with at least
Frontiers in Genetics | www.frontiersin.org

Step 2: Joint Exploration and
Characterization

As previously shown, several clinical variables were associated
with more than one omics data-type in both selected data-sets.
Such observations may indicate that some (if not all) those
5
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omics profiles are coordinated (or at least some of their features
are). Therefore, the next step in the STATegra framework was
to investigate and quantify a potential coordination.
Thus, instead of looking at the PCA-derived components of
mRNA and miRNA separately, we investigated the existence of
components (or factors) shared by both omics (Gomez-Cabrero
et al., 2019). Intuitively, while in PCA we projected using the
main components per omic (refer to Supplementary
Figures 2B, 3A as examples), we next aimed to identify projections
where the components are informative for more than one datatype simultaneously (refer to Figures 2A,C). In summary, when
analyzing the variability of data-types A and B, we aimed to
identify components associated to both A and B (shared
components), components associated only to A, and components
associated only to B (distinctive components).
Multi-data-set component analysis methodologies have three
key steps: (a) model selection, (b) subspace recovery, and (c)
estimation of robustness. In (a) model selection, we aimed to
identify the correct model, which means the exact number of
common (shared) components and the number of distinctive
components per data-type. The determination of model selection,
although fundamental, remains an open question (van der
Kloet et al., 2016; Måge et al., 2019); hence, no final function

has yet been included in the STATegRa package. However,
we explored several methods [JIVE (Lock et al., 2013), PCA-GCA
(Smilde et al., 2017), and pESCA (Song et al., 2020)]. Both,
common and distinctive components obtained for each method
are summarized in Supplementary Table 5. In our experience,
the selected method depends on the nature of the data [as
shown in (Måge et al., 2019)]. We do however recommend
the use of several methodologies to establish more robust
insights. While identifying the best model is an open challenge,
we considered – based on the estimates – using the results
from pESCA (Song et al., 2020), specifically pESCA (1%). Once
the number of shared and distinctive components was determined,
the subspace recovery (identification of loads and scores for
the components) should be conducted using the same
methodology used to identify space. Finally, to address robustness
estimation we refer to the method in Måge et al. (2019).
In the current data-sets we were prioritizing a gene-centric
analysis for both data-sets (GBM and SKCM); therefore, we posed
two scenarios; the joint analysis of mRNA and miRNA, and
the joint analysis of mRNA and methylation. We acknowledge
that there are tools in development for integrating more than
two omics; see for instance (Srivastava et al., 2013) and its
application in Gomez-Cabrero et al. (2019).

A

C

B

D

FIGURE 2 | Multi-omics component analysis. (A,C) Component-based representation of Glioblastoma Multiforme (GBM) and Skin Cutaneous Melanoma (SKCM)
joint exploration; mRNA + miRNA (left) and mRNA + methylation (right). First and second common components (or auxiliary if only one common component is
found) are shown. Samples are colored based on gene expression subtype for GBM and primary site of disease for SKCM. (B,D) Heatmap representation of –log10
(p-values) of the statistical test between metadata and common and distinctive components of GBM and SKCM joint analysis; mRNA + miRNA (left) and
mRNA + methylation (right). Color ranges from white to black, understood as p-values with no significance to significant p-values. Based on the nature of the
variables, p-values were obtained by association, correlation, or using a survival test. Radiations rri, dts, and dipd denote, respectively, “Radiations radiation regimen
indication,” “Days to submitted specimen dx,” and “Date of initial pathologic diagnosis.” See Supplementary Tables 3, 4 for a detailed description of the variables.

Frontiers in Genetics | www.frontiersin.org
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GBM data-set: we identified seven shared components between
mRNA and miRNA and one between mRNA and DNAm (refer
to Supplementary Table 5). Figure 2A shows two PC score
plots; the association between components (shared and distinctive)
and clinical variables is shown in Figure 2B. After investigating
all pairs of “share components vs. factors,” we observed that at
least one shared component was significantly associated (Bonferroni
adjusted value of p < 0.05) with: “gene expression subtype”
derived from (Verhaak et al., 2010; mRNA-miRNA, mRNADNAm), survival outcome (mRNA-miRNA), and age (mRNAmiRNA; Figure 2B). No significant relationship was seen between
gene expression subtype and survival outcome (Supplementary
Figure 4, value of p = 0.06), although a relationship between
age and survival outcome was observed (adjusted value of
p <0.05). Based on these results, we hypothesized a coordination
between the mRNA and miRNA profiles, and such coordination
is associated with survival. Consequently, we also considered that
integrating both data types will contribute to increasing the
knowledge regarding GBM survival. We identified a limited global
coordination when considering the mRNA and DNAm profiles.
SKCM data-set: seven shared components were identified
between mRNA and miRNA profiles, and four common
components between mRNA and DNAm profiles (refer to
Supplementary Table 5). Figure 2C shows two PC score plots,
and the association between components (shared and distinctive)
and clinical variables is shown in Figure 2D. At least one
component identified is significantly associated with the primary
site of the disease for both mRNA-miRNA and mRNA-DNAm
pairs and the disease stage for the mRNA-miRNA pair (refer
to Supplementary Material; Bonferroni adjusted value of p
<0.05). Based on these results, we concluded that mRNA,
miRNA and DNAm are globally coordinated, and this is mainly
associated with the primary site of the disease. Therefore, the
integration of the three data-types may contribute to increase
the knowledge on SKCM primary site.
Importantly, based on the complexity of the data, the joint
exploration may allow data-type specific related batch effects (identified
in Step 1) from batch effects associated with sample collection
(which will be associated to all omics). Interestingly, more than
two omics (blocks) can be analyzed to identify shared components
(Srivastava et al., 2013; Argelaguet et al., 2018; Song et al., 2020).
The next challenge, Step 3, was to leverage the coordination
identified among omics to gain statistical power to identify
the relevant features that explain the SuS.

encodings, ranges, and data distributions; and (d) it models the
correlation structures present in the data producing unbiased/
calibrated p-values, an interpretable metric (Pesarin and Salmaso, 2010).
OmicsNPC first analyses each data-type separately through
a permutation-based scheme. Currently, omicsNPC uses the
package limma or survival (coxph) for computing statistics
and p-values; however, the user may also customize the functions
(refer to “Materials and Methods”). The resulting permutedbased p-values may be combined using Tippett’s (aimed to
identify findings supported by at least one omics modality),
Liptak’s (by most omics modalities), or Fisher’s (intermediate
behavior between Tippett and Liptak) combination function.
Following the original NPC, omicsNPC (Karathanasis et al.,
2016) makes minimal assumptions: as permutation is employed
throughout the process, no parametric form is assumed for
the null distribution of the statistical tests, and the main
requirement is that samples are freely exchangeable under the
null-hypothesis. This frees the researcher from the need of
defining and modeling between dataset dependencies. Most
importantly, it provides global p-values for assessing the overall
association of related features across different data modalities
with the specified outcome (Pesarin and Salmaso, 2010).
GBM analysis: we aimed to investigate GBM survival through
its relationship with omic features corrected for age, based on
the association identified in Supplementary Figure 5. We only
used samples profiled for all data-types (n = 515 and n = 83
for the mRNA-miRNA and mRNA-DNAm pairs, respectively).
Table 1 (Overlapping samples column) presents the NPC outputs.
When the NPC is applied on “mRNA and miRNA,” the
integration allowed identifying 23 new genes and four new
miRNAs. For “mRNA and DNAm,” the integration allowed
identification of 106 new genes and 150 new CpG sites.
TABLE 1 | Non-parametric combination analysis results of two-omics data from
the GBM and SKCM projects.
GBM

Step 3: Integrative Differential Analysis,
omicsNPC

In Step 3 we used NPC to increase the statistical power for
the analysis of the SuS (Pesarin and Salmaso, 2010). Briefly,
NPC non-parametrically combines p-values from associated
features, such as a miRNA and one of its target genes measured
on overlapping sets of samples. We used the omicsNPC
(Karathanasis et al., 2016) included in the STATegRa package,
specifically tailored for the characteristics of omics data.
The main advantages of the NPC include: (a) high statistical power
with minimal assumptions; (b) wide applicability on different study
designs; (c) it allows integrating data modalities with different
Frontiers in Genetics | www.frontiersin.org

SKCM

mRNA + miRNA

Overlapping
samples

Whole
dataset

mRNA dimension
mRNA significant
miRNA dimension
miRNA significant
mRNA-miRNA total pairs
NPC_Fisher significant pairs
New mRNA from NPC
New miRNA from NPC
mRNA + DNAm
mRNA dimension
mRNA significant
Methylation dimension
Methylation significant
mRNA-methylation total pairs
NPC_Fisher significant pairs
New mRNA from NPC
New methylation sites from
NPC

7.814 × 515
1
325 × 515
1
24,665
27
23
4

7.814 × 523
4
323 × 518
1
24,665
50
43
7

9,491 × 104
216
239 × 104
6
20,225
114
48
14

9,620 × 83
2
57,645 × 83
1
57,645
150
106
150

9,620 × 523
7
57,645 × 95
0
57,645
332
174
332

9,564 × 104
277
55,729 × 104
12
55,729
432
116
428

Significance was considered for a False Discovery Rate <0.05. Bold values highlight the
number of significant features.
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SKCM analysis: we explored the omics characterization associated
to the primary site of the disease. When the NPC was applied
on “mRNA and miRNA,” the integration allowed identifying 48
new genes and 14 new miRNAs. For “mRNA and DNAm,” the
integration allowed identifying 116 new genes and 428 new CpG
sites. This increase of the statistical power was expected based
on the results from the joint exploration (Figure 2).

counterpart (Supplementary Table 6), which may be explained
by unaccounted inter-data-sets correlations that inflate the
significance of the p-values.

Step 4: Exploratory Analysis and
Determination of the Framework’s Added
Value

The STATegra framework provided novel genes, miRNAs, and
CpG sites for the two selected cases in comparison to unimodal
analyses. We investigated if such novel elements could also
provide new insights at gene-set level. For this, we made use
of the GeneSetCluster (Ewing et al., 2020), a tool that summarizes
gene-set analysis (GSA) results derived from multiple analyses.
It allows identifying core-results by clustering gene-sets and
posterior exploration; furthermore, it analyzes the integration
of more than one gene-set (which could be derived from more
than one omic) simultaneously. When investigating SKCM,
we compared three GSA: (Ramos et al., 2017) using genes
derived from mRNA single-omic analysis, (Gomez-Cabrero
et al., 2019) using genes derived from mRNA-miRNA NPC
analysis, and (Gomez-Cabrero et al., 2014) genes in (GomezCabrero et al., 2019) not identified in (Ramos et al., 2017).
We observed that the set of genes in (Ramos et al., 2017)
identified several relevant canonical pathways, which are also
identified in (Gomez-Cabrero et al., 2019) and (Gomez-Cabrero
et al., 2014); but, especially, (Gomez-Cabrero et al., 2014, 2019)

Alternatives to Step 3

Including samples available for a sub-set of data-types: when
doing the NPC analysis, we considered samples available for
both omics. However, in the case of GBM we discarded a large
number of samples. In (Karathanasis et al., 2016; Ewing et al.,
2019), we modified the NPC permutation protocol to include
the discarded samples. We observed that the use of all samples
allowed us to identify a larger number of novel features (“mRNA
and miRNA” identified 43 new genes instead of 23; for complete
results refer to Table 1, Column Whole data-set).
Parametric version: The NPC requires a large number of
permutations, which is time consuming. To address this, the
STATeRra package includes a parametric combination
methodology (Benjamini and Heller, 2008; Karathanasis et al.,
2016). This parametric approach is a faster alternative to NPC,
which we suggest to use in preliminary explorations. In our
analyses, the parametric approach generated a larger number
of significant results in comparison to the non-parametric

A

B

FIGURE 3 | GeneSetCluster analysis. Each heatmap depicts the gene-set to gene-set RR distance (Ewing et al., 2020). In each case several gene-set analyses
have been conducted. Red (yes)/black (no) shows which gene-sets have been identified for each gene-set analysis. (A) GBM and (B) SKCM. In SKCM, clusters
presented as black lines are those associated to discoveries through multi-omics integration.
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GSA identified many additional relevant pathways as shown
in Figure 3B for Canonical Pathways analysis (see box strokes
on clusters). In the case of GBM, four GSAs were conducted
with the following pair combinations: (a) “considering only
samples with all omics available (OVERLAP)” or “considering
all samples (ALL),” and (b) “considering all identified genes”
or “considering genes only identified by NPC.” We observed
major differences in the summarized gene-sets between
OVERLAP vs. ALL; see for instance Figure 3A, when analyzing
“Gene Ontology – Biological Functions” (Blake et al., 2015).
The use of GeneSetCluster allowed us to demonstrate the added
value of the STATegra framework. Furthermore, it is also a
tool for multi-omics GSA integrative analysis that we consider
as part of the STATegra framework. We plan to integrate such
tools continuously to the STATegRa package.

Most have been previously associated with cancer and particularly
to glioblastoma. We also compare the identified miRNAs with
existing miRNA-derived survival signatures (Srinivasan et al.,
2011); only miR222 is identified in the single-omic analysis,
while three additional miRNAs (miR31, miR221, and miR200b)
are identified by STATegra.
With the analysis of GSA, STATegra identifies new genesets, e.g., the TREM1 signaling pathway, previously associated
with GBM (Kluckova et al., 2020). In SKCM we investigated
the omics association with the primary site of disease. In
addition to the newly identified genes (refer to Table 1), the
major STATegra-associated novel insights are derived from GSA
analysis as shown in Figure 3B, particularly regarding the
identification of the IL8 signaling, which is known to be relevant
in SKCM (Shoshan et al., 2016; Tobin et al., 2019).
Importantly, the new results are not derived only because of
the application of the tools, but also because the application of
their combination as a framework (see also Figure 1). For
instance, the outcome of the Component Analysis provides insights
into which clinical variables to investigate or which combination
of omics to prioritize in the next steps. Furthermore, as shown,
the outcome of the NPC (identification of features by a singleomic or by paired-multi-omic-features) can be leveraged in the
GeneSetCluster tool to identify pathways derived from singleomic or coordinated among omics as shown in Figure 3. Adding
new tools to the framework or modifying the existing ones
should aim to generate greater synergies between the selected tools.
It is important to point out that we are not comparing our
analysis against the original publications: GBM (McLendon
et al., 2008; Brennan et al., 2013) and SKCM (Akbani et al.,
2015). The idea is to compare a generic framework with singleomic approaches. Moreover, since the questions and data-sets
used are different from those in the original TCGA publications,
a back-to-back comparison is not justified.
The results generated by STATegra show the added value
of a general integrative framework. Still, we acknowledge that,
similarly to Operations Research there is “no-free-lunch”
(Wolpert and Macready, 1997). Generic frameworks provide
an initial approximation to any integrative analysis. Once
completed, they may be further customized – and therefore
further optimized – to account for the characteristics of the
data and considered SuS. Still, the STATegra framework’s value
is its solid integration starting point, and - after being applied
in many projects – generic rules can be extracted to allow
an easier and faster customization.
Frameworks as the one we present here or complementary
ones aimed to supervised learning (Rohart et al., 2017) are
becoming increasingly necessary due to the amount of growing
multi-omics data, particularly in the context of single-cell
multi-omics (Colomé-Tatché and Theis, 2018). Further
developments are required in multi-omics visualization (González
et al., 2012), simulated data (Martínez-Mira et al., 2018), or
further exploitation of Component Analysis as shown in (SteinO’Brien et al., 2018), among others. Thus, we consider that
the STATegra framework is the starting point that will be further
developed over time. The next immediate steps are the inclusion
of pESCA (Song et al., 2020) for multi-omic component analysis

DISCUSSION
There are many bioinformatics integrative tools (Gomez-Cabrero
et al., 2014; Yugi et al., 2016; Hasin et al., 2017; Argelaguet
et al., 2018; Shafi et al., 2019). However, when carrying out
multi-omics analysis, as a rule, researchers use custom pipelines
that combine some of the available tools. While every multiomics data combination is different, we believe that a general
framework is key to gain knowledge for an “optimized” integrated
research analysis in the future. We here present the STATegra
framework, a multi-omics integrative pipeline, the result of
integrative analyses done over the last decade (Karathanasis
et al., 2016; Carlström et al., 2019; Ewing et al., 2019, 2020;
Fernandes et al., 2019). In the two chosen case studies used
to evaluate the STATegra framework, GBM and SKCM, we show
through a consecutive four-step process (Figure 1), how single
omics integration generates additional information. Step 2,
Component Analysis, quantifies the coordination of the different
data-types, a key phase to identify where omic-combination
can be leveraged, and Step 3 -Non-Parametric Combination
is used to gain statistical power. In both case studies, we detect
a greater number of genes as shown in Table 1. Interestingly
and following the gene expression vs. DNA Methylation relation,
in the case of the statistically significant pair of features identified
in the mRNA-DNAm analysis, were showing a bimodal – but
mostly negative – distribution of the correlation between gene
expression and DNA methylation (see Supplementary Figure 6).
Step 4 examines the added value of the biological-insights of
the features identified by the integration process.
In GBM we examine the association of the omics profiles
with survival. In comparison to single-omic analysis, the
STATegra framework identifies additional genes already known
to be associated with GBM such as CAST, ATF5, GANAB
[glycoprotein associated with GBM cancer stem cells (Dai et al.,
2011)], ICAM [overexpressed in bevacizumab-resistant GBM
(Piao et al., 2017)], CORO1A [upregulated in GBM (Berezovsky
et al., 2014)], LYN [in vitro association of enhanced survival
of GBM cells (Liu et al., 2013)], MET (proto-oncogene) and
STAT5 [enhances GBM cells migration, survival (Roos et al.,
2018), and proliferation (Feng and Cao, 2014)], among others.
Frontiers in Genetics | www.frontiersin.org
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and GeneSetCluster (Ewing et al., 2020) for multi-omic
exploratory analysis within the STATegRa Bioconductor package.

authors reviewed the manuscript and were part of the review of
the results of the analysis. All authors contributed to the article
and approved the submitted version.
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